Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Bristol Myers Faces $6.7 Billion Lawsuit After Judge Allows Key Shareholder Claims to Proceed 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Bayer AG (ETR: BAYGN) delivered a robust performance in the third quarter of 2025, reporting a 138% surge in core earnings per share to €0.57, up from €0.24 a year earlier. The German healthcare and agriculture giant attributed the growth to improved margins in its Crop Science division and continued momentum in new pharmaceuticals, despite currency headwinds and litigation-related payouts affecting cash flow.
Group sales rose 1% on a currency- and portfolio-adjusted basis to €9.7 billion, though reported revenue slipped 3% due to a €0.4 billion foreign exchange impact. EBITDA before special items jumped 21% to €1.5 billion, driven primarily by stronger results in Crop Science. However, free cash flow declined to €0.6 billion from €1.1 billion, reflecting higher litigation expenses. Net financial debt decreased 7% to €32.7 billion.
Crop Science, Bayer’s largest business unit, posted 1% growth (cpa) to €3.9 billion, supported by a 22% rise in corn seed and traits from increased U.S. planting and Latin American demand. Non-glyphosate herbicides rose 7%, while soybean and cotton seed sales declined due to regulatory setbacks. The division’s EBITDA margin climbed to 4.5% from 0.9%.
Pharmaceuticals reported flat sales at €4.3 billion, as soaring demand for Nubeqa (+56%) and Kerendia (+85%) offset a 31% drop in Xarelto amid generic competition. Eylea sales fell 11%, though its 8 mg version accounted for 27% of total revenue. Divisional EBITDA fell 5% to €1 billion.
Consumer Health grew 2% (cpa) to €1.4 billion, led by strong dermatology and digestive health segments.
For the first nine months of 2025, Bayer posted €34.1 billion in sales (+1% cpa) and €4.29 core EPS (+7%). The company reaffirmed its 2025 outlook, targeting sales between €46–48 billion and EBITDA before special items of €9.7–10.2 billion.
